Clinical Trial Update: Subcutaneous Ig NextGen 16% in PID Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Subcutaneous Immunoglobulin NextGen 16% in primary immunodeficiency has completed. The update notes completion but does not include tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Subcutaneous Immunoglobulin NextGen 16% (immunoglobulin G (IgG) subcutaneous formulation)

Snippet

Sponsor: CSL Limited | Conditions: Primary Immunodeficiency (PID) | Phase 3 | Status: COMPLETED